Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Vertex Pharmaceuticals Incorporated : Trump's Pick to Lead FDA Has Backing of Big Pharma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2017 | 01:45pm CET
By Joseph Walker 

Scott Gottlieb, the veteran health-care investor and physician nominated to lead the U.S. Food and Drug Administration, has strong backing from the pharmaceuticals industry as he prepares to put his stamp on the agency.

The Senate is expected to conduct a final vote as soon as this week to confirm Dr. Gottlieb's appointment as FDA commissioner.

Dr. Gottlieb is well known by many drug-industry executives. He worked for years as a consultant to companies including GlaxoSmithKline PLC and Vertex Pharmaceuticals Inc., spoke frequently at health-care and investor conferences, and wrote hundreds of essays and op-eds, often advocating for the FDA to approve drugs faster and loosen regulations on off-label marketing.

Dr. Gottlieb favors free-market strategies to bring down drug costs, including by increasing the rate of generic drug approvals at the FDA. He has also questioned the wisdom of allowing U.S. consumers to import brand-name drugs from countries like Canada, where they cost less, in part because of safety concerns -- a viewpoint shared by drugmakers.

"He agrees with the basic concept of the pharmaceutical industry: the need to have drugs come to market quickly, viewing the bureaucracy as necessary but [it] can get in the way of innovation," says Ronny Gal, a stock analyst at Sanford C. Bernstein & Co.

Company officials say they expect Dr. Gottlieb to push the FDA to accelerate its adoption of more-flexible approaches to evaluating new drugs and clinical trials. His experience as a physician and senior FDA official during the George W. Bush administration should help him garner support from the agency's rank-and-file staff to implement his agenda, executives say.

He "sounds like a progressive person who wants to get things done," said Eli Lilly & Co. Chief Executive David Ricks in an interview. "He's got experience in the agency already. He's a doctor and a cancer survivor. Sounds to me like he has a balanced perspective."

Dr. Gottlieb's extensive prior business relationships with pharmaceutical companies have spurred criticism from some Democrats and public advocacy groups. In April, five Senate Democrats questioned Dr. Gottlieb's commitment to fighting opioid addiction because of his work as a paid expert witness for a fentanyl-drug maker later acquired by Teva Pharmaceutical Industries Ltd. Public Citizen, a liberal watchdog group, said that Dr. Gottlieb was "entangled in an unprecedented web of close financial and business ties to the pharmaceutical industry."

Dr. Gottlieb has said he would recuse himself for one year from FDA decisions on more than 20 companies where he has potential conflicts of interest. "I understand how important impartiality of this agency is," Dr. Gottlieb said at his Senate confirmation hearing in April. "I don't want to do anything in my conduct to reduce people's confidence in the agency's mission."

Dr. Gottlieb earned at least $645,000 from drug companies and trade groups from the beginning of 2016 through the first two months of 2017, according to his disclosure statements.

He served for seven years on a GlaxoSmithKline board that manages the company's research and development investments, providing "a valuable perspective on the U.S. health-care and payer environment," said a GSK spokeswoman. As FDA commissioner, Dr. Gottlieb "will help ensure that the FDA maintains its focus on innovation and protecting public health by expeditiously approving safe and effective new treatments for patients," she said.

Dr. Gottlieb has also been supportive of loosening FDA restrictions on off-label marketing, where companies advertise uses for their drugs that haven't been cleared by the agency. He has advocated allowing companies to distribute such information to doctors so long as it is truthful and non-misleading.

There are numerous alternatives to "FDA's current regime -- which virtually bans off-label promotion -- that would promote FDA's public health goals even better than the current regime does," Dr. Gottlieb wrote in expert testimony in 2015 on behalf of Amarin Corp., in a lawsuit the company filed against the FDA over its off-label marketing policies.

Like other of President Donald Trump's nominees, Dr. Gottlieb has been critical of the agency he is nominated to oversee. He wrote in a 2012 essay that the FDA has a "harmful culture" that mistrusts doctors to prescribe drugs appropriately, leading officials to have "an excessive desire for certainty" that new medicines are safe and effective before they are approved, he wrote.

The FDA has several methods for accelerating approvals, such as granting conditional approval if studies show the drug is "reasonably likely" to help patients live longer or have other benefits. Some FDA divisions have embraced the faster methods, but other divisions are still very "rigid," says Ron Cohen, chief executive of Acorda Therapeutics Inc. "Even if you bring them evidence of benefit to patients, it's still an uphill climb."

Dr. Gottlieb said in April that he would create "consistency to how different parts of the FDA" use their powers.

Some researchers question how much further the FDA can go in speeding up drug approvals without lowering its standards. More than two-thirds of drug approvals last year were completed under "priority review," where the FDA makes an approval decision within six months instead of the standard 10 months, according to the FDA.

"The FDA is already one of the fastest regulatory agencies in the world, " says Aaron Kesselheim, an associate professor of medicine at Harvard Medical School. "Faster for faster's sake is not wise."

--Peter Loftus contributed to this article.

Write to Joseph Walker at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS
11/20 S&P 500 MOVERS : Vrtx, dlph
11/16 VERTEX PHARMACEUTICALS : Announces Presentations of Data at North American Cysti..
11/15 Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Pe..
11/14 Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
11/13 VERTEX PHARMACEUTICALS : Earnings Review and Free Research Report: Vertex’s Reve..
11/12 VERTEX PHARMACEUTICALS : Latest Trial Data on Vertex CF Therapies and New Combos..
11/10 VERTEX PHARMACEUTICALS : Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor..
11/09 VERTEX PHARMACEUTICALS : to Present at the Credit Suisse Healthcare Conference o..
11/09 VERTEX PHARMACEUTICALS : Announces New $750,000 Program to Support the Work of t..
11/09 VERTEX PHARMACEUTICALS : Announces Presentations of Data at North American Cysti..
More news
News from SeekingAlpha
11/10 European advisory group backs expanded use for Vertex's Orkambi
11/08 Sarepta Therapeutics Will Continue To Ride High On EXONDYS 51's Success In 20..
11/03 Vertex's tezacaftor/ivacaftor showed significant treatment benefit in late-st..
11/01 YOUR DAILY PHARMA SCOOP : Gilead In NASH, Geron Gets A Boost, AstraZeneca's Onco..
10/30 YOUR DAILY PHARMA SCOOP : Gilead's Unappreciated Opportunity, Merck's Keytruda S..
Financials ($)
Sales 2017 2 372 M
EBIT 2017 537 M
Net income 2017 256 M
Finance 2017 1 079 M
Yield 2017 -
P/E ratio 2017 154,43
P/E ratio 2018 81,24
EV / Sales 2017 15,0x
EV / Sales 2018 12,8x
Capitalization 36 580 M
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 183 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS100.10%36 580
GILEAD SCIENCES1.16%94 196
REGENERON PHARMACEUTICALS6.67%41 388
GENMAB4.43%11 537
EXELIXIS, INC.76.93%7 589
BLUEBIRD BIO INC164.51%7 580